Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease
Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease
The aim of the study is to evaluate if patients' personality could be considerate as
 predictive factor of quality of life after the establishment of continuous infusion of
 dopaminergic treatments to observe if there are predictive personality's profiles of specific
 therapeutic response (Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) or
 continuous infusion).
Parkinson's disease leads to quality of life degradation, especially at level of motor
 complications. Second line treatment can be proposed to patients. There are deep brain
 stimulation and two treatments by continuous perfusion: subcutaneous apomorphine infusion and
 intrajejunal infusion of levodopa-carbidopa. These treatments allow improvement of
 end-of-dose akinesia, dyskinesia, and a diminution of treatments per os. Nonetheless, they
 also lead to some side effects and complications. Currently, there are no scientific data to
 compare the efficacy of these two techniques on motor and non-motor symptoms. Choice is made
 according to the profile of the patient mainly based on side effects risks, and
 practitioner's habits. There are still no predictive factors clearly defined to judge of the
 best efficacy of these treatments according to the patients. Moreover, in an additional study
 named PSYCHO-STIM, the investigator have discovered that personality can be a predictive
 factor of quality of life amelioration 1 year after deep brain stimulation. It's why the
 investigator would like to test personality as a predictive factor of therapeutic response
 after both continuous perfusions that are available for the patients. Thus, patients
 beginning a treatment by subcutaneous apomorphine infusion or intrajejunal infusion of
 levodopa-carbidopa will be included. The investigator will evaluate their personality with
 the questionnaire "TCI" (Temperament and Character Inventory) and the investigator will
 assess their quality of life (PDQ-39), looking for the percentage of amelioration 6 months
 after the treatment by continuous infusion started. As secondary criteria, depression (HAMD),
 anxiety (HAMA), apathy (LARS), motility (MDS-UPDRS) and clinic severity (CGIS) will also be
 accessed before the treatment change and six months later.
Inclusion Criteria:

 -  Patients having Parkinson's disease according to United Kingdom Parkinson's Disease
 Society Brain Bank (UKPDSBB) criteria

 -  All Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and
 in need of the establishment of a second line treatment by subcutaneous apomorphine
 infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical
 care of their Parkinson's disease

 -  Patient able to give its free and informed consent

 -  Patient having a social security

 Exclusion Criteria:

 -  Patients presenting atypical Parkinson's syndrome

 -  Patients having a deep brain stimulation

 -  Patient having a psychiatric disease such as: mood disorders, psychotic disorder…

 -  Patients presenting a cognitive decline evaluated by a Montreal Cognitive Assessment
 (MoCA) score inferior to 24

 -  None ability to give its consent

 -  Patients unable to realize the tests provided in the context of this study

 -  Patients under supervision, curators, or legal guardian

 -  Patients non-affiliated to a social security

 -  Patients in exclusion period of another study.